T-cell immunotherapy with a chimeric receptor against CD38 is effective in eradicating chemotherapy-resistant B-cell lymphoma cells overexpressing survivin induced by BMI-1

被引:6
作者
Bhattacharyya, J. [1 ]
Mihara, K. [1 ]
Kitanaka, A. [2 ]
Yanagihara, K. [3 ]
Kubo, T. [3 ]
Takei, Y. [4 ]
Kimura, A. [1 ]
Takihara, Y. [5 ]
机构
[1] Hiroshima Univ, Dept Hematol & Oncol, Res Inst Radiat Biol & Med, Hiroshima, Japan
[2] Kagawa Univ, Fac Med, Dept Lab Med, Takamatsu, Kagawa 760, Japan
[3] Yasuda Womens Univ, Fac Pharm, Dept Life Sci, Hiroshima, Japan
[4] Nagoya Univ, Grad Sch Med, Dept Biochem, Nagoya, Aichi 4648601, Japan
[5] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Stem Cell Biol, Hiroshima, Japan
关键词
NON-HODGKINS-LYMPHOMA; MOLECULAR MARKER; RITUXIMAB; PROGNOSIS; IMPROVES;
D O I
10.1038/bcj.2012.21
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:e75 / e75
页数:3
相关论文
共 17 条
[1]   Overexpression of BMI-1 correlates with drug resistance in B-cell lymphoma cells through the stabilization of survivin expression [J].
Bhattacharyya, Joyeeta ;
Mihara, Keichiro ;
Ohtsubo, Motoaki ;
Yasunaga, Shin'ichiro ;
Takei, Yoshifumi ;
Yanagihara, Kazuyoshi ;
Sakai, Akira ;
Hoshi, Masaharu ;
Takihara, Yoshihiro ;
Kimura, Akiro .
CANCER SCIENCE, 2012, 103 (01) :34-41
[2]   A Systematic Review of Occupational Exposure to Particulate Matter and Cardiovascular Disease [J].
Fang, Shona C. ;
Cassidy, Adrian ;
Christiani, David C. .
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2010, 7 (04) :1773-1806
[3]   Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma [J].
Fu, Kai ;
Weisenburger, Dennis D. ;
Choi, William W. L. ;
Perry, Kyle D. ;
Smith, Lynette M. ;
Shi, Xinlan ;
Hans, Christine P. ;
Greiner, Timothy C. ;
Bierman, Philip J. ;
Bociek, R. Gregory ;
Armitage, James O. ;
Chan, Wing C. ;
Vose, Julie M. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) :4587-4594
[4]  
Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412
[5]   Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20m Ab) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention [J].
Jazirehi, AR ;
Bonavida, B .
ONCOGENE, 2005, 24 (13) :2121-2143
[6]   T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia [J].
Kalos, Michael ;
Levine, Bruce L. ;
Porter, David L. ;
Katz, Sharyn ;
Grupp, Stephan A. ;
Bagg, Adam ;
June, Carl H. .
SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (95)
[7]   The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement [J].
Le Gouill, Steven ;
Talmant, Pascaline ;
Touzeau, Cyrille ;
Moreau, Anne ;
Garand, Richard ;
Juge-Morineau, Nadine ;
Gaillard, Fanny ;
Gastinne, Thomas ;
Milpied, Noel ;
Moreau, Philippe ;
Harousseau, Jean Luc ;
Avet-Loiseau, Herve .
HAEMATOLOGICA, 2007, 92 (10) :1335-1342
[8]   Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis [J].
Mihara, K ;
Chowdhury, M ;
Nakaju, N ;
Hidani, S ;
Ihara, A ;
Hyodo, H ;
Yasunaga, S ;
Takihara, Y ;
Kimura, A .
BLOOD, 2006, 107 (01) :305-308
[9]   Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma [J].
Mihara, Keichiro ;
Yanagihara, Kazuyoshi ;
Takigahira, Misato ;
Kitanaka, Akira ;
Imai, Chihaya ;
Bhattacharyya, Joyeeta ;
Kubo, Takanori ;
Takei, Yoshifumi ;
Yasunaga, Shin'ichiro ;
Takihara, Yoshihiro ;
Kimura, Akiro .
BRITISH JOURNAL OF HAEMATOLOGY, 2010, 151 (01) :37-46
[10]   Activated T-cell-mediated Immunotherapy With a Chimeric Receptor Against CD38 in B-cell Non-Hodgkin Lymphoma [J].
Mihara, Keichiro ;
Yanagihara, Kazuyoshi ;
Takigahira, Misato ;
Imai, Chihaya ;
Kitanaka, Akira ;
Takihara, Yoshihiro ;
Kimura, Akiro .
JOURNAL OF IMMUNOTHERAPY, 2009, 32 (07) :737-743